CA3244873A1 - Preventive treatment for migraines - Google Patents
Preventive treatment for migrainesInfo
- Publication number
- CA3244873A1 CA3244873A1 CA3244873A CA3244873A CA3244873A1 CA 3244873 A1 CA3244873 A1 CA 3244873A1 CA 3244873 A CA3244873 A CA 3244873A CA 3244873 A CA3244873 A CA 3244873A CA 3244873 A1 CA3244873 A1 CA 3244873A1
- Authority
- CA
- Canada
- Prior art keywords
- atogepant
- treatment
- migraine
- baseline
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269105P | 2022-03-09 | 2022-03-09 | |
| US63/269,105 | 2022-03-09 | ||
| US202263347265P | 2022-05-31 | 2022-05-31 | |
| US63/347,265 | 2022-05-31 | ||
| US202263404352P | 2022-09-07 | 2022-09-07 | |
| US63/404,352 | 2022-09-07 | ||
| US202363480365P | 2023-01-18 | 2023-01-18 | |
| US63/480,365 | 2023-01-18 | ||
| PCT/US2023/064027 WO2023173005A2 (en) | 2022-03-09 | 2023-03-09 | Preventive treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244873A1 true CA3244873A1 (en) | 2023-09-14 |
Family
ID=87936018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244873A Pending CA3244873A1 (en) | 2022-03-09 | 2023-03-09 | Preventive treatment for migraines |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230321055A1 (https=) |
| EP (1) | EP4489856A4 (https=) |
| JP (1) | JP2025508004A (https=) |
| CN (1) | CN119421710A (https=) |
| AU (1) | AU2023231645A1 (https=) |
| CA (1) | CA3244873A1 (https=) |
| MX (1) | MX2024010878A (https=) |
| WO (1) | WO2023173005A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4408418A1 (en) | 2021-09-27 | 2024-08-07 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190374520A1 (en) * | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20210121541A1 (en) * | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
| CN116390712A (zh) * | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
-
2023
- 2023-03-09 MX MX2024010878A patent/MX2024010878A/es unknown
- 2023-03-09 CA CA3244873A patent/CA3244873A1/en active Pending
- 2023-03-09 AU AU2023231645A patent/AU2023231645A1/en active Pending
- 2023-03-09 EP EP23767687.9A patent/EP4489856A4/en active Pending
- 2023-03-09 WO PCT/US2023/064027 patent/WO2023173005A2/en not_active Ceased
- 2023-03-09 CN CN202380026078.8A patent/CN119421710A/zh active Pending
- 2023-03-09 US US18/181,228 patent/US20230321055A1/en active Pending
- 2023-03-09 JP JP2024552730A patent/JP2025508004A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230321055A1 (en) | 2023-10-12 |
| JP2025508004A (ja) | 2025-03-21 |
| CN119421710A (zh) | 2025-02-11 |
| WO2023173005A2 (en) | 2023-09-14 |
| MX2024010878A (es) | 2024-09-17 |
| WO2023173005A3 (en) | 2023-11-23 |
| EP4489856A4 (en) | 2026-04-15 |
| AU2023231645A1 (en) | 2024-09-12 |
| EP4489856A2 (en) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3244873A1 (en) | Preventive treatment for migraines | |
| JP7480261B2 (ja) | 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法 | |
| CN112437659B (zh) | 用于治疗抑郁症的右美沙芬和安非他酮的组合 | |
| Nayak | A review of montelukast in the treatment of asthma and allergic rhinitis | |
| US12090148B2 (en) | Treatment of migraine | |
| US10537568B2 (en) | Use of levocetirizine and montelukast to ameliorate inflammation following radiation exposure | |
| JP2024156984A (ja) | 難治性全身型重症筋無力症の処置のための方法 | |
| DK3033101T3 (en) | PROCEDURES FOR REDUCING EXACT EXERCISE RATES FOR ASTMA USING BENRALIZUMAB | |
| US20190247333A1 (en) | Method of reduction in convulsive seizure frequency | |
| US20170260276A1 (en) | Treatment for rheumatoid arthritis | |
| CN121221782A (zh) | 用于治疗抑郁的nk-1拮抗剂组合物和方法 | |
| WO2024081718A1 (en) | Cgrp receptor antagonist for the treatment of migraine | |
| CN110719778B (zh) | 用于治疗抑郁的组合物和方法 | |
| TW202330614A (zh) | 抗ｔｒｅｍ２抗體及其用途 | |
| Kimura et al. | Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study | |
| Pan et al. | Administration Timing of Amoxicillin Does Not Influence the Efficacy of Vonoprazan‑Amoxicillin Dual Therapy for Helicobacter pylori Eradication | |
| Clark | Top 60 most important medications used in an orofacial pain treatment center | |
| Boucher et al. | Emerging Drugs for Amyotrophic Lateral Sclerosis | |
| O’Gorman et al. | Comparative Efficacy of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) versus Rizatriptan in the Acute Treatment of Migraine | |
| HK40074123A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| HK40074121A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| Krymchantowski | Overview of Upcoming Treatments for Migraine. Too Much Enthusiasm | |
| JP4372723B2 (ja) | 慢性疼痛の治療のための医薬の製造に有用な組成物 | |
| HK40100385A (zh) | 用於神经精神病症的抗抑郁剂和右美沙芬的组合 | |
| CN118900846A (zh) | 抗trem2抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240822 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240827 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240827 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240827 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |